#1 Clinical Trials Search in Europe

Pentetic Acid

Pentetic acid, also known as DTPA (diethylenetriaminepentaacetic acid), is being studied in clinical trials for its potential to remove gadolinium from the body and treat various conditions. This article explores the ongoing research on pentetic acid, its applications in gadolinium deposition disease, and other potential uses in medical treatments.

Table of Contents

What is Pentetic Acid?

Pentetic acid, also known as DTPA (Diethylenetriaminepentaacetic acid), is a medication used primarily for removing certain harmful metals from the body. It belongs to a class of drugs called chelating agents. Pentetic acid comes in two main forms: Calcium DTPA (Ca-DTPA) and Zinc DTPA (Zn-DTPA)[1].

Other names for pentetic acid include[2]:

  • Calcium DTPA (Ca-DTPA)
  • Zinc DTPA (Zn-DTPA)
  • Diethylenetriaminepenta-acetate

Uses of Pentetic Acid

Pentetic acid is primarily used for the following purposes:

  1. Removing heavy metals: It is approved by the U.S. Food and Drug Administration (FDA) for removing certain radioactive heavy metals from the body[2].
  2. Treating Gadolinium Deposition Disease (GDD): Pentetic acid is being studied for treating patients who have retained gadolinium (a contrast agent used in MRI scans) in their bodies and developed symptoms after the scan[2].
  3. Measuring kidney function: Some forms of pentetic acid are being investigated as a way to measure glomerular filtration rate (GFR), which is an indicator of kidney function[3].

How Pentetic Acid Works

Pentetic acid works as a chelating agent. This means it can bind to certain metals in the body, forming a stable compound that can be excreted through urine. This process helps remove harmful metals from the body[1].

In the case of Gadolinium Deposition Disease, pentetic acid is thought to bind to gadolinium that has been retained in the body after an MRI scan, allowing it to be eliminated through urine[2].

Administration and Dosage

Pentetic acid is typically administered intravenously (through a vein). The exact dosage and administration schedule can vary depending on the specific condition being treated and the form of pentetic acid being used. Here’s an example of how it might be given:

  • For Gadolinium Deposition Disease: Patients may receive 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by a saline infusion. This process is then repeated with Zn-DTPA the following day. The two-day procedure may be repeated multiple times over several weeks[2].

It’s important to note that the dosage and administration should always be determined by a healthcare professional based on the individual patient’s needs and condition.

Potential Side Effects

While pentetic acid has been used for over 60 years and is generally well-tolerated, like all medications, it can have side effects. Some potential side effects may include:

  • Changes in mineral levels in the body
  • Kidney function changes
  • Nausea or vomiting
  • Headache
  • Dizziness

However, it’s important to note that not everyone experiences side effects, and your doctor will monitor you closely during treatment[2].

Ongoing Research

Pentetic acid is currently being studied for various uses:

  • Gadolinium Deposition Disease: Researchers are investigating whether pentetic acid can help reduce symptoms in patients who have retained gadolinium after MRI scans[2].
  • Kidney Function Measurement: Some forms of pentetic acid are being studied as a potential way to measure kidney function more accurately[3].
  • Cancer Treatment: There is ongoing research to determine if pentetic acid could help improve the effectiveness of chemotherapy in certain types of leukemia by reducing metal levels in the bone marrow and blood[4].

It’s important to note that while these studies show promise, more research is needed to fully understand the potential benefits and risks of using pentetic acid for these purposes.

Aspect Details
Main Uses in Trials Gadolinium removal, treatment of gadolinium deposition disease, assessment of kidney function
Administration Method Intravenous infusion, often as Ca-DTPA and Zn-DTPA on alternating days
Treatment Duration Varies by study, ranging from a few infusions to 40-50 infusions over a year
Potential Benefits Gadolinium removal, symptom reduction in GDD, improved quality of life
Monitored Outcomes Gadolinium levels in urine, pain scores, cognitive function, quality of life measures
Safety Considerations Monitoring for renal function changes, hypocalcemia, hypoglycemia
Other Applications Potential use in peripheral artery disease, critical limb ischemia

FAQ

  • What is pentetic acid (DTPA) and how is it being used in clinical trials? Pentetic acid, or DTPA, is a chelating agent being studied for its ability to remove gadolinium from the body after MRI scans. It's also being investigated for treating gadolinium deposition disease and other conditions involving heavy metal toxicity.
  • How is pentetic acid administered in clinical trials? In most trials, pentetic acid is administered intravenously. For example, one study uses Ca-DTPA on day 1 and Zn-DTPA on day 2, with each dose given over 1 minute followed by a saline infusion.
  • What are the potential benefits of pentetic acid treatment? Potential benefits include removal of retained gadolinium, reduction of symptoms associated with gadolinium deposition disease (such as pain and cognitive issues), and improved quality of life for affected patients.
  • Are there any side effects or risks associated with pentetic acid treatment? While pentetic acid is generally well-tolerated, studies are monitoring for potential side effects such as changes in renal function, hypocalcemia, hypoglycemia, and heart failure. However, specific side effects vary depending on the study and dosage.
  • How long does pentetic acid treatment typically last in clinical trials? Treatment duration varies by study. Some trials involve a series of infusions over several months, while others may include up to 40-50 infusions over a year. The exact duration depends on the specific trial protocol and condition being treated.

Ongoing Clinical Trials on Pentetic Acid

  • Study on the Effects of R3R01 on Reducing Protein in Urine for Patients with Diabetic Kidney Disease

    Recruiting

    2 1 1
    Investigated drugs:
    Denmark

Glossary

  • Pentetic Acid (DTPA): A chelating agent used to bind and remove heavy metals from the body, including gadolinium.
  • Gadolinium: A rare earth metal used as a contrast agent in MRI scans to enhance image quality.
  • Gadolinium Deposition Disease (GDD): A condition where gadolinium is retained in the body after MRI scans, potentially causing various symptoms.
  • Chelation: The process of binding metal ions to remove them from the body.
  • Ca-DTPA: Calcium DTPA, a form of pentetic acid used in chelation therapy.
  • Zn-DTPA: Zinc DTPA, another form of pentetic acid used in chelation therapy.
  • Glomerular Filtration Rate (GFR): A measure of kidney function, sometimes assessed using pentetic acid as a tracer.
  • Critical Limb Ischemia: A severe blockage in the arteries of the lower extremities, which can lead to tissue death.
  • Peripheral Artery Disease (PAD): A circulatory condition where narrowed blood vessels reduce blood flow to the limbs.
  • Quality of Life (QOL): A measure of an individual's well-being and ability to perform daily activities.

References

  1. https://clinicaltrials.gov/study/NCT02947022
  2. https://clinicaltrials.gov/study/NCT05359835
  3. https://clinicaltrials.gov/study/NCT02300376
  4. https://clinicaltrials.gov/study/NCT03630991